Kymera Therapeutics Stock Performance
| KYMR Stock | USD 44.98 1.47 3.38% |
The company secures a Beta (Market Risk) of -0.22, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Kymera Therapeutics are expected to decrease at a much lower rate. During the bear market, Kymera Therapeutics is likely to outperform the market. At this point, Kymera Therapeutics has a negative expected return of -0.11%. Please make sure to verify Kymera Therapeutics' information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Kymera Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Kymera Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's primary indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return 4.78 | Five Day Return 1.31 | Year To Date Return 79.84 | Ten Year Return 37.07 | All Time Return 37.07 |
1 | Disposition of 7150 shares by Esposito Pamela of Kymera Therapeutics at 48.7526 subject to Rule 16b-3 | 09/17/2024 |
2 | Kymeras IND Application for STAT6 Degrader Gets FDA Clearance | 10/10/2024 |
3 | Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 | 10/23/2024 |
4 | Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Im... | 10/24/2024 |
5 | Acquisition by Albers Jeffrey W. of 16000 shares of Kymera Therapeutics at 31.2 subject to Rule 16b-3 | 10/25/2024 |
6 | Kymera Therapeutics Inc Q3 2024 Everything You Need To Know Ahead Of Earnings | 10/30/2024 |
7 | Kymera Therapeutics Releases Earnings Results, Beats Estimates By 0.01 EPS | 11/01/2024 |
8 | Earnings Update Kymera Therapeutics, Inc. Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts | 11/04/2024 |
9 | Wellington Management Group LLPs Strategic Acquisition in Kymera Therapeutics Inc | 11/08/2024 |
10 | FMR LLC Bolsters Stake in Kymera Therapeutics Inc | 11/13/2024 |
11 | Kymera Therapeutics Now Covered by Stephens - MarketBeat | 11/18/2024 |
| Begin Period Cash Flow | 74.5 M | |
| Free Cash Flow | -137.3 M |
Kymera |
Kymera Therapeutics Relative Risk vs. Return Landscape
If you would invest 4,975 in Kymera Therapeutics on August 24, 2024 and sell it today you would lose (477.00) from holding Kymera Therapeutics or give up 9.59% of portfolio value over 90 days. Kymera Therapeutics is currently does not generate positive expected returns and assumes 3.057% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Kymera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kymera Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kymera Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kymera Therapeutics, and traders can use it to determine the average amount a Kymera Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0364
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KYMR |
Estimated Market Risk
| 3.06 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.11 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kymera Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kymera Therapeutics by adding Kymera Therapeutics to a well-diversified portfolio.
Kymera Therapeutics Fundamentals Growth
Kymera Stock prices reflect investors' perceptions of the future prospects and financial health of Kymera Therapeutics, and Kymera Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kymera Stock performance.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.91) % | ||||
| Operating Margin | (19.28) % | ||||
| Current Valuation | 2.36 B | ||||
| Shares Outstanding | 64.77 M | ||||
| Price To Book | 3.16 X | ||||
| Price To Sales | 32.18 X | ||||
| Revenue | 78.59 M | ||||
| Gross Profit | (117.42 M) | ||||
| EBITDA | (143.2 M) | ||||
| Net Income | (146.96 M) | ||||
| Cash And Equivalents | 392.31 M | ||||
| Cash Per Share | 7.61 X | ||||
| Total Debt | 84.67 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 4.60 X | ||||
| Book Value Per Share | 13.79 X | ||||
| Cash Flow From Operations | (102.83 M) | ||||
| Earnings Per Share | (2.34) X | ||||
| Market Capitalization | 2.82 B | ||||
| Total Asset | 575.76 M | ||||
| Retained Earnings | (530.75 M) | ||||
| Working Capital | 319.63 M | ||||
About Kymera Therapeutics Performance
Assessing Kymera Therapeutics' fundamental ratios provides investors with valuable insights into Kymera Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Kymera Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -1.7 K | -1.8 K | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.34) | (0.35) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.37) | (0.35) |
Things to note about Kymera Therapeutics performance evaluation
Checking the ongoing alerts about Kymera Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kymera Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kymera Therapeutics generated a negative expected return over the last 90 days | |
| Kymera Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 78.59 M. Net Loss for the year was (146.96 M) with loss before overhead, payroll, taxes, and interest of (117.42 M). | |
| Kymera Therapeutics currently holds about 392.31 M in cash with (102.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.61. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Kymera Therapeutics Now Covered by Stephens - MarketBeat |
- Analyzing Kymera Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kymera Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Kymera Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kymera Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kymera Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kymera Therapeutics' stock. These opinions can provide insight into Kymera Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.